These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11398305)

  • 21. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo.
    Andersson PG; Jespersen LT
    Cephalalgia; 1986 Mar; 6(1):51-4. PubMed ID: 3516408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC
    Cephalalgia; 2013 Oct; 33(13):1122-31. PubMed ID: 23588793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo].
    Hoernecke R; Doenicke A
    Med Klin (Munich); 1993 Nov; 88(11):642-8. PubMed ID: 8295604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic treatment of migraine in children: a systematic review of medication trials.
    Damen L; Bruijn JK; Verhagen AP; Berger MY; Passchier J; Koes BW
    Pediatrics; 2005 Aug; 116(2):e295-302. PubMed ID: 16061583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacologic treatment of acute migraine attack in children].
    Cuvellier JC; Joriot S; Auvin S; Vallée L
    Arch Pediatr; 2005 Mar; 12(3):316-25. PubMed ID: 15734131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repetitive dihydroergotamine nasal spray for treatment of refractory headaches: an open-label pilot study.
    Weintraub J
    Curr Med Res Opin; 2006 Oct; 22(10):2031-6. PubMed ID: 17022862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
    Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
    CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
    Aellig WH; Rosenthaler J
    Eur J Clin Pharmacol; 1986; 30(5):581-4. PubMed ID: 3758146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium.
    Kelley NE; Tepper DE
    Headache; 2012 Jan; 52(1):114-28. PubMed ID: 22211870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.
    Edwards KR; Norton J; Behnke M
    Headache; 2001; 41(10):976-80. PubMed ID: 11903525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human pharmacokinetics of dihydroergotamine administered by nasal spray.
    Humbert H; Cabiac MD; Dubray C; Lavène D
    Clin Pharmacol Ther; 1996 Sep; 60(3):265-75. PubMed ID: 8841149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia.
    Tepper SJ; Kori SH; Borland SW; Wang MH; Hu B; Mathew NT; Silberstein SD
    Headache; 2012 Jan; 52(1):37-47. PubMed ID: 22106843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
    Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.